| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status | 
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NA | Fedratinib Hydrochloride | Inrebic | 100mg | Chemotherapy | Enzyme Inhibitor | JAK2, FLT3 | Yes | 2019 | In Use | |||
| Tovorafenib | Ojemda | 25mg, 100mg | Chemotherapy | Enzyme Inhibitor | BRAF, CRAF | Yes | 2024 | In Use | ||||
| NA | Ruxolitinib | Jakafi | 20 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
| J7527 | Everolimus | Afinitor, Afinitor Disperz | 0.25 mg | Chemotherapy | Enzyme Inhibitor | mTOR | Yes | 2009 | Jan 1, 2013 | In Use | ||
| NA | Niraparib | Zejula | 100 mg | Chemotherapy | Enzyme Inhibitor | PARP | Yes | 2017 | In Use | |||
| J8561 | Everolimus | Afinitor, Afinitor Disperz | 0.25 mg | Chemotherapy | Enzyme Inhibitor | mTOR | Yes | 2009 | Jan 1, 2012 | Dec 31, 2012 | No Longer Used | |
| C9239 | Temsirolimus | Torisel | 1 mg | Chemotherapy | Enzyme Inhibitor | mTOR | No | 2007 | Jan 1, 2008 | Dec 31, 2008 | No Longer Used | |
| NA | Umbralisib | Ukoniq | 260.2mg | Chemotherapy | Enzyme Inhibitor | PI3Kδ, CK1ε, ABL1, CXCL12, CCL19 | Yes | 2021 | In Use | |||
| NA | Alpelisib | Piqray | 150mg | Chemotherapy | Enzyme Inhibitor | PI3K | Yes | 2019 | In Use | |||
| NA | Vemurafenib | Zelboraf | 240 mg | Chemotherapy | Enzyme Inhibitor | BRAF | Yes | 2011 | In Use | |||
| NA | Alpelisib | Piqray | 200mg | Chemotherapy | Enzyme Inhibitor | PI3K | Yes | 2019 | In Use | |||
| NA | Ruxolitinib | Jakafi | 25 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
| NA | Ruxolitinib | Jakafi | 10 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
| J0870 | Imetelstat | Rytelo | 1mg | Chemotherapy | Enzyme Inhibitor | Telomerase | No | 2024 | Dec 17, 2024 | In Use | ||
| NA | Enasidenib mesylate | Idhifa | 50 mg | Chemotherapy | Enzyme Inhibitor | IDH2 | Yes | 2017 | In Use | |||
| NA | Panobinostat | Farydak | 20 mg | Chemotherapy | Enzyme Inhibitor | HDAC | Yes | 2015 | In Use | |||
| C9265 | Romidepsin | Istodax | 1 mg | Chemotherapy | Enzyme Inhibitor | HDAC | No | 2009 | Jul 1, 2010 | Dec 31, 2010 | No Longer Used | |
| NA | Ruxolitinib | Jakafi | 5 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
| NA | Rucaparib | Rubraca | 250 mg | Chemotherapy | Enzyme Inhibitor | PARP | Yes | 2017 | In Use | |||
| NA | Panobinostat | Farydak | 10 mg | Chemotherapy | Enzyme Inhibitor | HDAC | Yes | 2015 | In Use | |||
| J9057 | Copanlisib | Aliqopa | 1mg | Chemotherapy | Enzyme Inhibitor | PI3K | No | 2017 | In Use | |||
| Olutasidenib | Rezlidhia | 150mg | Chemotherapy | Enzyme Inhibitor | IDH1 | Yes | 2022 | In Use | ||||
| Momelotinib | Ojjaara | Multiple | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2023 | In Use | ||||
| NA | Rucaparib | Rubraca | 300 mg | Chemotherapy | Enzyme Inhibitor | PARP | Yes | 2017 | In Use | |||
| NA | Ruxolitinib | Jakafi | 15 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | 
                The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
                not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
                specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
                truly not available.
            
         An official website of the United States government
 An official website of the United States government
		 Home
 Home 
                             
                    